Literature DB >> 16369883

Flumequine in the goat: pharmacokinetics after intravenous and intramuscular administration.

R Villa1, P Cagnardi, O Sonzogni, S Carli.   

Abstract

The pharmacokinetics of flumequine, administered intravenously and intramuscularly at a single dose of 20 mg/kg, was investigated in healthy goats. After intravenous injection, flumequine distributed rapidly (t1/2alpha = 0.87+/-0.15 h) but was eliminated slowly (t1/2beta = 7.12+/-1.27 h); mean clearance (Cl) and volume of distribution (Vdss) were 0.32+/-0.03 (L/(h x kg) and 1.22+/-029 (L/kg), respectively. After intramuscular administration, the peakserum concentration (Cmax = 7.40+/-0.5 microg/ml) was reached in about 1.5 h (Tmax) and bioavailability was about 93%. Estimated flumequine serum levels following repeated intramuscular administration of the aqueous suspension used in the study (7.23+/-0.7 microg/ml and 4.82+/-0.47 microg/ml at intervals of 8 and 12 h, respectively) indicated that to maintain serum levels above MIC values for susceptible bacteria a dosage regimen of 20 mg/kg every 12 h is necessary by the intramuscular route.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16369883     DOI: 10.1007/s11259-005-3867-7

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  12 in total

1.  In vitro activity of flumequine in comparison with several other antimicrobial agents against five pathogens isolated in calves in The Netherlands.

Authors:  D J Mevius; H J Breukink; A S van Miert
Journal:  Vet Q       Date:  1990-10       Impact factor: 3.320

2.  In vitro activity of five tetracyclines and some other antimicrobial agents against four porcine respiratory tract pathogens.

Authors:  A Pijpers; B Van Klingeren; E J Schoevers; J H Verheijden; A S Van Miert
Journal:  J Vet Pharmacol Ther       Date:  1989-09       Impact factor: 1.786

3.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

4.  Pharmacokinetics of flumequine in sheep after intravenous and intramuscular administration: bioavailability and tissue residue studies.

Authors:  J M Delmas; A M Chapel; V Gaudin; P Sanders
Journal:  J Vet Pharmacol Ther       Date:  1997-08       Impact factor: 1.786

5.  Clinical pharmacokinetics of flumequine in calves.

Authors:  G Ziv; S Soback; A Bor; B Kurtz
Journal:  J Vet Pharmacol Ther       Date:  1986-06       Impact factor: 1.786

6.  Effect of tick-borne fever on the disposition of sulphadimidine and its metabolites in plasma of goats.

Authors:  J F Nouws; S M Anika; A S van Miert; T B Vree; M Baakman; C T van Duin
Journal:  Res Vet Sci       Date:  1986-05       Impact factor: 2.534

Review 7.  Aspects of chemistry in the development of the 4-quinolone antibacterial agents.

Authors:  G C Crumplin
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

8.  Sulfadimidine metabolism in vitro: II. Comparative studies in cultured rat, goat, sheep and cattle hepatocytes.

Authors:  G A van 't Klooster; B J Blaauboer; J Noordhoek; A S van Miert
Journal:  J Vet Pharmacol Ther       Date:  1993-12       Impact factor: 1.786

9.  Pharmacokinetical aspects of flumequine and therapeutic efficacy in Escherichia coli infection in poultry.

Authors:  E Goren; W A De Jong; P Doornenbal
Journal:  Avian Pathol       Date:  1982       Impact factor: 3.378

10.  Disposition of radiolabeled flumequine in rat and dog.

Authors:  L I Harrison; D Schuppan; S R Rohlfing; A R Hansen; J F Gerster; C S Hansen; M L Funk; R E Ober
Journal:  Drug Metab Dispos       Date:  1986 Sep-Oct       Impact factor: 3.922

View more
  1 in total

1.  Distribution of Flumequine in Intestinal Contents and Colon Tissue in Pigs after Its Therapeutic Use in the Drinking Water.

Authors:  Jose M Rodríguez; M Jose Diez; Matilde Sierra; Juan J Garcia; Nelida Fernandez; Raquel Diez; Ana M Sahagun
Journal:  Animals (Basel)       Date:  2021-05-23       Impact factor: 2.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.